The following is a summary of “Steroid-resistant nephrotic syndrome due to renal-limited thrombotic microangiopathy and ...

Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

The chronic kidney disease drug development landscape is evolving at an unprecedented pace, driven by breakthrough approvals, billion-dollar mergers and acquisitions, and increasing regulatory support ...

subsequently renamed the hepatitis B surface antigen (HBsAg), Combes and coworkers first described the occurrence of membranous nephropathy (MN) due to glomerular deposition of Australian antigen ...

Specifically, this antibody has been used to treat membranous nephropathy, cryoglobulinemic glomerulonephritis, systemic lupus erythematosus (SLE) and ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA ...

Doctors revealed such creams can cause membranous nephropathy. Research indicated that untreated creams with mercury can lead to kidney damage, while unregulated products remain prevalent in markets.

which along with PNH and IgAN include atypical haemolytic uraemic syndrome (aHUS), C3 glomerulopathy (C3G), and idiopathic membranous nephropathy (IMN). IgAN is a key focus for Novartis ...

Choreo LLC lifted its holdings in argenx SE (NASDAQ:ARGX – Free Report) by 4.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange ...

SE (NASDAQ:ARGX – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty-two ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst ...

The drug is also in mid-stage clinical trials for primary membranous nephropathy (PMN) and antibody-mediated transplant rejection and is in phase 1 for lupus nephritis. According to the American ...

Background: Rituximab (RTX) is a monoclonal antibody that selectively targets CD20 and is frequently used in the treatment of membranous nephropathy (MN). Analysis of the therapeutic efficacy and ...